Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Catecholaminergic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Catecholaminergic means "related to catecholamines". The catecholamine neurotransmitters include dopamine, epinephrine (adrenaline), and norepinephrine (noradrenaline). A catecholaminergic agent (or drug) is a chemical which functions to directly modulate the catecholamine systems in the body or brain. Examples include adrenergics and dopaminergics.
Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
InactiveUS6894024B2Suppress plasma blood levelReducing norepinepherine levelPeptide/protein ingredientsMetabolism disorderHigh energyMortality rate
Owner:ASTRAZENECA PHARMA LP
Novel agents for preventing and treating disorders involving modulation of the RyR receptors
InactiveUS20070049572A1Improve bindingLow affinityBiocideOrganic active ingredientsSIDS - Sudden infant death syndromeDisease cause
The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Multicolor non-toxic hair dye and preparation method and dying method thereof
InactiveCN109846742AWell mixedSimple and fast operationCosmetic preparationsHair cosmeticsCatecholamineHair dyes
The invention discloses a multicolor non-toxic hair dye and a preparation method and dying method thereof. The multicolor non-toxic hair dye is characterized by comprising an A agent and a B agent, wherein the A agent comprises catecholamine or a catecholamine derivative, a thickening agent, a pH-regulating agent, a pigment additive and water; and the B agent comprises an oxidizer, a thickening agent, a pH-regulating agent and water. The catecholamines substances are adopted and oxidized by the oxidizer, so that melanin analogues high in surface adhesion properties are formed, and are coated to the surface of hair in an in situ manner, and the surface color of hair can be changed. Compared with a conventional hair dye, the hair dye disclosed by the invention is free from toxin, and betterin biological safety. The hair dye is high in dying stability, low in cost, simple in preparation technology and favorable for environment prevention, can well meet color diversity requirements, doesnot need to be heated when being used, can be applied to the surface of the hair after the A agent and the B agent are uniformly mixed, and is simple to operate during dying, short in dying time, andwidely applied to various crowds.
Owner:SOUTHWEST MEDICAL UNIVERISTY
Electrophysiology catheter
ActiveCN105615990AElectrode stickingEffective stickingSurgical instruments for heatingCatecholaminergic polymorphic ventricular tachycardiaBiological activation
The invention discloses an electrophysiology catheter. The electrophysiology catheter comprises a catheter bendable section, a catheter main body section and a catheter handle which are connected in sequence, wherein the far end of the catheter bendable section is provided with an annular ring, a plurality of annular electrodes are distributed on the annular ring, the catheter handle is provided with a ring adjusting push button, the catheter is internally provided with a first cavity, the first cavity is provided with ring adjusting wires in a penetrating manner, and the ring adjusting wires are respectively connected with the ring adjusting push button and the far end of the annular ring. According to the electrophysiology catheter provided by the invention, the far end of the catheter bendable section is provided with the annular ring, and the push button of the catheter handle and the ring adjusting wires arranged in the catheter are used for controlling the bending shape of the far end of the catheter and the diameter of the annular ring, so that the plurality of electrodes arranged on the far end of the catheter effectively attach to the mouth part or the inner wall of the renal artery, the purpose of treating the refractory hypertension and other cardiovascular diseases, such as atrial fibrillation and catecholaminergic polymorphic ventricular tachycardia related to sympathetic nerve excessive activation is achieved, and the operation is safe and reliable.
Owner:上海鸿电医疗科技有限公司
New preparation method of hydrochloride landiolol
ActiveCN101768148AEasy to operateLow costOrganic chemistryCardiovascular disorderMedicinal chemistryHydrochloride
The invention discloses a new preparation method of hydrochloride landiolol; the route has simple operation, environmental-protection, is suitable for organic synthesis method of the industrial mass production, and can realize industrialization. The hydrochloride landiolol is selective beat1 receptor blocker, mainly antagonizes the beat1 receptor existing in the heart, and improves tachycardia arrhythmia through inhibiting the increase of heart rate caused by catecholamine.
Owner:KUNMING JIDA PHARMA
Transgenic animal model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and use thereof
The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2).Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.
Owner:PRIORI SILVIA G +1
Method of Gene Transfer for the Treatment of Recessive Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
ActiveUS20130059905A1Calcium binding proteinsGene therapyGene deliveryCatecholaminergic polymorphic ventricular tachycardia
The present invention concerns a method for the treatment of recessive Catecholaminergic Polymorphic Ventricular Tachycardia comprising delivering a gene into a cardiac cell.
Owner:INSTI CLINICI SCII MAUGERI S P A SB
Agents for preventing and treating disorders involving modulation of the RyR receptors
InactiveUS7704990B2BiocideOrganic active ingredientsVentricular dysrhythmiaSIDS - Sudden infant death syndrome
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Agents for preventing and treating disorders involving modulation of the RyR receptors
ActiveUS8022058B2Organic active ingredientsBiocideVentricular dysrhythmiaSIDS - Sudden infant death syndrome
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Preparation and application of quality control substances of plasma type freeze-dried powder catecholamines and metabolites
PendingCN111208220AImprove uniformityImprove stabilityComponent separationMetaboliteInfectious Disorder
The invention relates to preparation and application of a quality control substances of plasma type freeze-dried powder catecholamines and metabolites, and the substance is prepared by the following main steps: collecting clinical fresh plasma-free for infectious disease screening, selecting samples with negative screening results, and mixing together for later use; adsorbing catecholamine substances and metabolites in the plasma by adopting activated carbon to obtain blank plasma; adding a standard stock solution of catecholamines and metabolites thereof into the blank plasma, and uniformly stirring; adding a stabilizer, an excipient, an antioxidant and a preservative into the plasma, and stirring until the components are completely dissolved; and sub-packaging the obtained plasma by using ampoule bottles according to specification requirements, and freeze-drying to prepare freeze-dried powder. The method can overcome the defects that catecholamine substances and metabolite quality control substances in fresh plasma and frozen plasma are unstable and are not easy to store for a long time and has the advantages of good uniformity and stability.
Owner:NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO LTD
Cardiac risk stratification by nos1ap genotyping
InactiveUS20110177503A1High riskElectrocardiographyMicrobiological testing/measurementGenotypeTagging SNP
A risk-conferring genetic modifier is found in a large LQTS cohort. A NOS1AP tag SNP genotype provides an additional clinical assessment, which helps assess risk and choice of therapeutic strategies in LQTS as well as other conditions such as Brugada Syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPTV).
Owner:FOND SALVATORE MAUGERI
Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
InactiveCN102224135AOrganic active ingredientsNervous disorderNeurological impairmentMammalian brain
The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications.
Owner:NSAB FILIAL AF NEUROSEARCH SVERIGE
Catecholamine substance magnetic molecularly imprinted polymer and preparation method and application thereof
ActiveCN111825814AHigh selectivityImprove adsorption capacityOther chemical processesPolymer scienceMolecularly imprinted polymer
The invention discloses a catecholamine substance magnetic molecularly imprinted polymer and a preparation method thereof. Fe3O4 is used as a carrier, and template molecules (methoxyepinephrine and dopamine are used as double template molecules), alpha-methacrylic acid and ethylene glycol dimethacrylate form a magnetic molecularly imprinted polymer under the action of azodiisobutyronitrile througha thermal free radical polymerization reaction. The preparation method comprises the following steps: taking magnetic Fe3O4 nanoparticles as a raw material; preparing vinylated Fe3O4 nanoparticles tomodify the surfaces of the vinylated Fe3O4 nanoparticles with carbon-carbon double bonds; preparing a magnetic molecularly imprinted polymer by adopting a surface molecular imprinting technology; theadsorbent has relatively strong selection capability and adsorbability on methoxyepinephrine, methoxynorepinephrine and 3-methoxytyramine molecules, has high adsorption capacity on a target to-be-detected object, can be recycled, and can be used for efficiently separating and enriching methoxyepinephrine, methoxynorepinephrine and 3-methoxytyramine molecules in a urine sample.
Owner:CHONGQING MEDICAL UNIVERSITY
Nutrigenomic methods to overcome carbohydrate bingeing and overeating
InactiveUS20130195827A1Blunt excessive appetite cravingIncreased energy expenditureBiocidePeptide/protein ingredientsRelapse preventionCatecholamine
This invention concerns Reward Deficiency Syndrome (RDS) and obesity, and the role of catecholaminergic pathways in aberrant substance-seeking behavior, in particular cravings for carbohydrates. Also described are new nutrigenomic formulas having unique combinations of ingredients having a generalized anti-craving effect are, which can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention, as well genetic testing for certain polymorphisms correlated with RDS behaviors.
Owner:BLUM KENNETH +3
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
ActiveUS11104697B2Sufficient amountIncrease in dopaminergic turnoverOrganic active ingredientsNervous disorderQuinolizineBenzo Quinolizine
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]guinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereofThe compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.The invention also relates to a new intermediate of said process.
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/aa581b85-f9ff-4819-b8f7-31512f3f34fc/US11104697-D00001.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/aa581b85-f9ff-4819-b8f7-31512f3f34fc/US11104697-D00002.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/aa581b85-f9ff-4819-b8f7-31512f3f34fc/US11104697-D00003.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
Owner:H LUNDBECK AS
Catecholamine-modified cellulose material as well as preparation method and application thereof in filter membrane
PendingCN113045678AReduce pollutionPromote rapid formationSemi-permeable membranesCellulose acetateEthyl group
The invention provides a catecholamine-modified cellulose material as well as a preparation method and application thereof in a filter membrane, belonging to the technical field of membrane separation. The catecholamine-modified cellulose material is prepared by grafting cellulose molecules with a catecholamine modifier through a Schiff base reaction, the cellulose molecules are one or more selected from a group consisting of cellulose, cellulose acetate, methyl cellulose and ethyl cellulose, and the catecholamine modifier is one or more selected from dopamine or noradrenaline. As the catecholamine modifier is strong in hydrophilicity, the water molecule binding capacity of the filter membrane can be greatly improved, protein adsorption difficulty is increased, and contamination on the surface of the filter membrane is reduced. Meanwhile, the passing speed of a solution can be increased due to the excellent hydrophilicity, and a water flux is increased. Moreover, the catecholamine modifier is a short-chain amphoteric molecule, and is grafted on a damaged main chain structure of cellulose through a Schiff base reaction, so the pore structure of the membrane can be improved, and the water flux is further improved.
Owner:NORTHEAST FORESTRY UNIVERSITY
3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.
Owner:INTEGRATIVE RES LAB SWEDEN
Microcapsule adrenomedullary cell for curing malignant, tumor pain and its preparing method
InactiveCN1408437AImprove survival rateAnalgesic effectAntipyreticAnalgesicsAdrenal glandCell survival rate
The microcapsule adrenomedullary cell for curing malignant tumor pain consists of ACA microcapsule or APA microcapsule embedded human or animal adrenomedullary cell and the microcapsule entrapped molecular weight is 68-97.4 KD. The microcapsule adrenomedullary cell for curing malignant tumor pain is prepared through five steps of: separation of adrenomedullary cell from human or animal adrenal gland, short period culture in culture liquid, microencapsulation of adrenomedullary cell with ACA or APA, freeze storing in liquid nitrogen and restoring temperature in 37 deg.C before use. The microcapsule adrenomedullary cell for curing malignant tumor pain is transplanted to under human arachnoid of tumor patient to produce obvious pain relieving effect and immune isolation.
Owner:TIANJIN CITY THIRD CENT HOSPITAL
Screening kit for malignant arrhythmia, establishment method and application of animal model
ActiveCN108588085AReveal the molecular mechanismBioreactor/fermenter combinationsBiological substance pretreatmentsCatecholamineVentricular tachycardia
The invention provides a screening kit for malignant arrhythmia, an establishing method and an application of the animal model. In the method one RyR2 mutation site (p. A690E) is detected in patient families with familial sudden cardiac death history and confirmed. A transgenic animal model is further applied, and a gene knock-in mouse is successfully built. The phenotype of sudden death and ventricular tachycardia induced by the mutation is verified by the mouse model, and the effects of mutation on the structure and function of calcium channel are further investigated by biochemistry, electrophysiology, cell and structural biology, disclosing the molecular mechanism of catecholaminergic polymorphic ventricular tachycardia (CPVT) induced by mutation. The method provides a new idea for thetreatment of CPVT and the prevention of sudden death, and can be applied to the mouse model to screen the arrhythmia treatment drugs.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL
Treatment or Prevention of Cancer or Cardiovascular Disease with Methenyltetrahydrofolate Synthetases
The present invention relates to a method of screening test substances for chemotherapeutic activity or for efficacy in treating cardiovascular disease by providing one or more cells transformed with a nucleic acid molecule encoding methenyltetrahydrofolate synthetase, contacting the cells with test substance(s), and identifying those test substances which modulate methenyltetrahydrofolate synthetase expression as candidates for such therapeutic use. Another aspect of the present invention relates to a method of measuring folate status in a sample by measuring methenyltetrahydrofolate synthetase expression or activity and / or catecholamine activity in the sample, all of which are correlated to folate status in the sample. The present invention can also be used to treat or prevent cancer or cardiovascular disease in a subject by administering to the subject a substance which modulates methenyltetrahydrofolate synthetase expression or activity and / or catecholamine activity.
Owner:CORNELL RES FOUNDATION INC
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
ActiveUS11111263B2Good effectIncrease in dopaminergic turnoverNervous disorderSugar derivativesQuinolizineBenzo Quinolizine
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereofThe compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.The invention also relates to new intermediates of said process.
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/b86984c2-b189-467b-9327-20133e6e8880/US11111263-D00001.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/b86984c2-b189-467b-9327-20133e6e8880/US11111263-D00002.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
![Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid](https://images-eureka.patsnap.com/patent_img/b86984c2-b189-467b-9327-20133e6e8880/US11111263-D00003.png "Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid")
Owner:H LUNDBECK AS
Substituted amines for treating cardiac diseases
ActiveUS10543212B2Superior CaMKII inhibitory actionOrganic active ingredientsOrganic chemistryDiseaseVentricular tachycardia
Owner:CARDURION PHARMA LLC
Novel optically active aminopentane derivative
A novel optically pure (-)-1-(Benzofuran-2-yl)-2-propylaminopentane as represented by the following formula, which contains no (+)-isomer, and the pharmaceutically acceptable acid salt thereof. These compounds have excellent CAE effect (catecholaminergic activity enhancer effect) which is the enhancing action of neurotransmitter catecholamine release, and are useful as psychotropic composition, antidepressants, composition for treating Parkinson's disease and / or Alzheimer's disease.
Owner:THE FUJIMOTO CO LTD
Method of gene transfer for the treatment of recessive catecholaminergic polymorphic ventricular tachycardia (CPVT)
ActiveUS20140309290A1Calcium binding proteinsAnimals/human peptidesGene deliveryCatecholaminergic polymorphic ventricular tachycardia
The present invention concerns a method for the treatment of recessive Catecholaminergic Polymorphic Ventricular Tachycardia comprising delivering a gene into a cardiac cell.
Owner:INSTI CLINICI SCII MAUGERI S P A SB
Heterocyclic compound
ActiveUS20180280389A1Superior CaMKII inhibitory actionOrganic active ingredientsOrganic chemistryDiseaseCatecholamine
The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof.
Owner:CARDURION PHARMA LLC
Use of catecholamines and related compounds as anti-angiogenic agents
Owner:NAT RES COUNCIL OF CANADA
Method of gene transfer for the treatment of recessive catecholaminergic polymorphic ventricular tachycardia (CPVT)
ActiveUS8859517B2BiocideSugar derivativesGene deliveryCatecholaminergic polymorphic ventricular tachycardia
Owner:INSTI CLINICI SCII MAUGERI S P A SB
Compositions and methods for treating or preventing catecholaminergic polymorphic ventricular tachycardia
PendingCN111194212AOrganic active ingredientsAnimal cellsVentricular tachycardiaCatecholaminergic polymorphic ventricular tachycardia
The present invention features AIP peptide and polynucleotide compositions, methods of using such compositions for the treatment of CPVT, as well as a human induced pluripotent stem cell derived cardiomyocyte model, useful in characterizing agents that modulate myocardial conduction and contraction.
Owner:CHILDRENS MEDICAL CENT CORP
Fused heteroaryl compounds and their use as camkii inhibitors
PendingUS20220098207A1Superior CaMKII inhibitory actionOrganic chemistryOrganic active ingredientsVentricular tachycardiaCatecholaminergic polymorphic ventricular tachycardia
The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the description,or a pharmaceutically acceptable salt thereof.
Owner:CARDURION PHARMA LLC
Method for treating equine laminitis
InactiveUS20100227895A1Minimize the possibilityRegulate plasma catecholamine levelBiocidePeptide/protein ingredientsTyrosineNiacin
A method for the treatment and preventative care of equine laminitis includes effective administration of the amino acid L-tyrosine, alone, or in conjunction with choline bitartrate, niacin, and / or d-calcium pantothenate to regulate and restore hormonal balance, blood pressure and normal catecholamine synthesis. Tyrosine administration fosters proper vasculation in the equine's body, and specifically promotes proper circulation in and to the hoof and laminae.
Owner:MPCO THE MAGIC POWDER
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com